SCHEMBL1765351

SCHEMBL1765351

O=C1CN(C(=O)c2cc(-c3cc(F)cc(Cl)c3)n(-c3cccc(Cl)c3)n2)CN1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPP1CA P62136 1/20 0.46
PTGS2 P35354 4/20 0.43
PTGS1 P23219 1/20 0.43
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
RXRG P48443 1/20 0.42
MALT1 Q9UDY8 2/20 0.42
CCKAR P32238 1/20 0.42
SLC5A1 P13866 4/20 0.41
MGLL Q99685 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHRNA7 P36544 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765529 0.96 PPP1CA (0.47) PPP1CAPTGS2PTGS1RXRARXRB
SCHEMBL1765378 0.92 CCKAR (0.46) PPP1CAPTGS2PTGS1MALT1CCKAR
SCHEMBL12597373 0.90 KDM1A (0.43) PPP1CAPTGS2PTGS1MALT1CCKAR
SCHEMBL1765049 0.90 SLC5A1 (0.44) PPP1CAPTGS2PTGS1MALT1CCKAR
SCHEMBL1765402 0.90 PTGS2 (0.52) PPP1CAPTGS2PTGS1MALT1CCKAR
SCHEMBL14995519 0.90 MARS1 (0.45) PTGS2PTGS1MALT1MGLLMEN1
SCHEMBL1526038 0.90 MEN1 (0.45) PPP1CAPTGS2PTGS1RXRARXRB
SCHEMBL14995482 0.90 MALT1 (0.45) PPP1CAPTGS2PTGS1RXRARXRB
SCHEMBL1764979 0.89 CCKAR (0.51) PPP1CAPTGS2PTGS1MALT1CCKAR
SCHEMBL1764968 0.89 KDM1A (0.44) PPP1CAPTGS2PTGS1MALT1CCKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO PPP1CA 1664/4885PTGS2 3497/4885PTGS1 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.